BioLight Announces IND FIling with FDA for Phase I/IIa Clinical Study for its Controlled Release Latanoprost Insert for the Treatment of Glaucoma

BioLight announces that ViSci, its wholly owned subsidiary, has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to conduct a Phase I/IIa clinical study with its subconjunctival Latanoprost controlled release insert for the treatment of glaucoma.

Link to the complete article

Link to Newsroom

Comments are closed